TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39513363
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg p.o. daily with nivolumab 240 mg i.v. on days 1 and 15 of a 28-day cycle
Study: 39513407
Drug: GLPG3970 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 350 mg + Sulfasalazine 1,000 mg
Study: 39513407
Drug: GLPG3970 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 350 mg + Methotrexate 7.5 mg
Study: 39513569
Drug: PEG-rhGH 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH 0.2 mg/kg/week (high dose)
Study: 39513569
Drug: PEG-rhGH 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH 0.1 mg/kg/week (low dose)
Study: 39514025
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg and 10 mg tamoxifen
Study: 39514247
Drug: EHR-based medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR-based medication alerts for DOAC prescriptions
Study: 39514267
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg/m2) combined with chemotherapy and cryoablation
Study: 39514431
Drug: Hybrid cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid cochlear implant with electric-acoustic stimulation (EAS)
Study: 39514693
Drug: Hyponatremia (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyponatremia (sodium <135 mmol/L)
Study: 39514693
Drug: Hypernatremia (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypernatremia (sodium >145 mmol/L)
Study: 39514693
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate sodium (≤138 mmol/L)
Study: 39514895
Drug: Facilitated initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Facilitated initiation of medications for AUD
Study: 39515186
Drug: oVRcome mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: oVRcome mobile application (self-managed virtual reality exposure therapy combined with cognitive-behavioural techniques)
Study: 39515186
Drug: Waitlist delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist delayed treatment group
Study: 39515361
Drug: Problem Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem Management for Moms (PM4M) programme, a ten-session treatment offered by phone or in person.
Study: 39515522
Drug: Concomitant eosinophil-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant eosinophil-lowering therapy
Study: 39515580
Drug: Ultra-brief pulse
Normalized name: BRIEF,ULTRA BRIEF LARGE TENA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-brief pulse right unilateral Electroconvulsive Therapy (ECT)
Study: 39515845
Drug: Online exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online exposure and response prevention behavioural therapy for tics
Study: 39515856
Drug: Individual target
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual target transcranial magnetic stimulation (IT-TMS) combined with antidepressant medication
Study: 39515867
Drug: Dexmedetomidine (0.4 µg/kg/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 µg/kg/h after anaesthesia induction until dural closure, then 0.08 µg/kg/h for 48 hours postoperatively)
Study: 39515988
Drug: 40% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% dextrose gel
Study: 39516358
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (Q28) with vandetanib 300 mg od (f + v)
Study: 39516370
Drug: E7389-LF 2.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7389-LF 2.1 mg/m plus nivolumab
Study: 39516454
Drug: Risankizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (150 mg, subcutaneous)
Study: 39516710
Drug: fampridine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: fampridine (10 mg twice daily for 3.5 days)
Study: 39517110
Drug: Ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted atazanavir (ATV/r) administered twice daily (BD)
Study: 39518090
Drug: Quality Indicators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality Indicators in the Treatment of NMIBC
Study: 39520634
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg as needed up to once daily for up to 52 weeks
Study: 39520893
Drug: MenACWY-CRM (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (single dose)
Study: 39521008
Drug: Concizumab prophylaxis
Normalized name: concizumab
DrugBank: Concizumab (DB12820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concizumab prophylaxis (1.0 mg/kg loading dose on day 1, followed by daily doses of 0.20 mg/kg, with options to adjust based on plasma concentration)
Study: 39521433
Drug: Durvalumab 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 20 mg/kg every four weeks
Study: 39521433
Drug: Chemotherapy every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy every three weeks for four to six cycles
Study: 39521460
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg buprenorphine maintenance daily dose
Study: 39521460
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg buprenorphine maintenance daily dose
Study: 39522018
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation intervention (8 tele-therapy sessions over 10 weeks)
Study: 39522090
Drug: Alteplase (low-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (low- or high-dose) plus standard of care (SOC)
Study: 39522541
Drug: Neoadjuvant toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant toripalimab (240 mg intravenously) every 2 weeks for two cycles followed by concurrent cisplatin (100 mg/m2)
Study: 39522541
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with concurrent cisplatin (100 mg/m2)
Study: 39522654
Drug: Amlitelimab 250
Normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlitelimab 250 mg every 4 weeks plus a 500-mg loading dose
Study: 39522654
Drug: Amlitelimab 125
Normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlitelimab 125 mg every 4 weeks
Study: 39522654
Drug: Amlitelimab 62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlitelimab 62.5 mg every 4 weeks
Study: 39522654
Drug: Amlitelimab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlitelimab (any dose) continued for 28 weeks after initial treatment
Study: 39522654
Drug: Amlitelimab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlitelimab (any dose) stopped after initial treatment
Study: 39522654
Drug: Amlitelimab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlitelimab (any dose)
Study: 39522824
Drug: eRT (FDG-PET-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: eRT (FDG-PET-guided dose painting and scheduled adaptive radiotherapy)
Study: 39522957
Drug: Baricitinib 4-mg
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4-mg equivalent
Study: 39522957
Drug: Baricitinib 2-mg
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2-mg equivalent
Study: 39522957
Drug: Baricitinib 1-mg
Normalized name: baricitinib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 1-mg equivalent
Study: 39523543
Drug: Nirmatrelvir/ritonavir (NMV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirmatrelvir/ritonavir (NMV/r) 300 mg/100 mg every 12 hours for 5 days
Study: 39523547
Drug: RSVpreF (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVpreF (120 µg)
Study: 39523681
Drug: Disease Severity
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease Severity Index (DSI) calculated from clearances of labelled cholates after oral and intravenous administration
Study: 39523878
Drug: Three standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three standard doses of inactivated COVID-19 vaccines
Study: 39523878
Drug: Two standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two standard doses plus a double dose of inactivated COVID-19 vaccines
Study: 39523878
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of inactivated COVID-19 vaccines in healthy controls
Study: 39524230
Drug: Acalabrutinib (monotherapy)
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib (monotherapy)
Study: 39525672
Drug: PIKA COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIKA COVID-19 vaccine booster dose
Study: 39525672
Drug: Inactivated COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated COVID-19 vaccine (Sinovac, China)
Study: 39525677
Drug: PIKA-adjuvanted recombinant
Normalized name: varicella zoster virus glycoprotein E
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (5 µg, 10 µg, and 20 µg)
Study: 39525677
Drug: PIKA-adjuvanted recombinant
Normalized name: varicella zoster virus glycoprotein E
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine
Study: 39525887
Drug: Subcutaneous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tissue of lipedema stages I, II, and III
Study: 39525887
Drug: Hypertrophied subcutaneous
Normalized name: DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertrophied subcutaneous tissue
Study: 39525940
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) using the Sanvello smartphone application for 4 weeks
Study: 39526777
Drug: Abscess capsule
Normalized name: MYCOBACTERIUM ABSCESSUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abscess capsule FDG signal
Study: 39526779
Drug: High-dose 5-ALA
Normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose 5-ALA (>40 mg/kg)
Study: 39526779
Drug: Low/standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low/standard dose 5-ALA (<30 mg/kg)
Study: 39526855
Drug: Low salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low salt diet (1.5 g/day) for 3 months
Study: 39527056
Drug: Zoledronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (5 mg) in the first year
Study: 39527056
Drug: Continuous denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous denosumab treatment (60 mg twice yearly)
Study: 39527056
Drug: Zoledronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate (5 mg) in the first year (ZOL subgroup with 3 or more years of denosumab treatment)
Study: 39527097
Drug: Nivolumab, trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab, trastuzumab, and FOLFOX chemotherapy (FOLFOX arm)
Study: 39527236
Drug: Upper Extremity
Normalized name: lymphedema garments, upper extremity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper Extremity Robotic Rehabilitation (RR) - ExoRehab X, Houston Bionics, twice/week for 6 weeks alongside conventional treatment.
Study: 39527516
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) intervention over 4 weeks
Study: 39528049
Drug: First Subsequent
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Subsequent Therapy (FST) with platinum-based chemotherapy and PARP inhibitor
Study: 39528058
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg plus EGb 761 160 mg daily
Study: 39528058
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg and clopidogrel 75 mg daily
Study: 39528111
Drug: Solriamfetol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol (75 mg/d for 3 days, then 150 mg/d for 2 weeks)
Study: 39528324
Drug: Tenofovir amibufenamide
Normalized name: Tenofovir amibufenamide
DrugBank: Tenofovir amibufenamide (DB18805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir amibufenamide therapy
Study: 39528489
Drug: Isatuximab (Isa)
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab (Isa) 20-mg/kg administered weekly in cycle 1, then biweekly
Study: 39528665
Drug: AUTO4 (TRBC1-directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUTO4 (TRBC1-directed autologous chimeric antigen receptor T cells)
Study: 39529054
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of CAF/kg
Study: 39529054
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of CAF/kg
Study: 39529054
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg of CAF/kg
Study: 39529169
Drug: Iparomlimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iparomlimab (200 mg or 3 mg/kg for patients with body weight < 40 kg, IV, Q3W) until disease progression, intolerable toxicities, withdrawal of consent, death, or up to 2 years.
Study: 39529175
Drug: Collaboration strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaboration strategies (e.g., staff co-location, communication quality)
Study: 39529199
Drug: Intermittent theta
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent theta burst stimulation (iTBS) delivered to the left dorsolateral prefrontal cortex (LDLPFC) once daily for 10 consecutive workdays, with parameters of 120% resting motor threshold, 50 Hz bursts repeated at 5 Hz, 600 pulses per session (total duration 3 min 9 s)
Study: 39529482
Drug: Dexmedetomidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.4 μg/kg over 10 min, followed by 0.4 μg/kg/h continuous infusion)
Study: 39529939
Drug: High-dose multistrain
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose multistrain probiotic mix (Sinquanon)
Study: 39530465
Drug: Personalized nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized nutrition and exercise intervention (high-protein diet with daily protein supplementation, functional training with strength and aerobic exercises)
Study: 39530558
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg intravenously every 4 weeks up to 6 months
Study: 39530574
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab vedotin 1.25 mg/kg (Days 1, 8, and 15)
Study: 39530627
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tarlatamab
Study: 39530627
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tarlatamab
Study: 39531369
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (FF/VI 100/25μg or UMEC/VI 62.5/25μg)
Study: 39531423
Drug: Pembrolizumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 400 mg every 6 weeks
Study: 39532348
Drug: Individualised transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised transfusion strategy (prescription of RBCT restricted to patients with Hb ≤9.0 g/dL and oxygen extraction ratio)
Study: 39532363
Drug: Social robot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social robot as cotherapist during 9 weekly sessions (B)
Study: 39532363
Drug: Baseline without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline without the robot during 4 weekly sessions (A)
Study: 39532363
Drug: Follow-up without
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up without the robot during 4 weekly sessions (C)
Study: 39532835
Drug: Entinostat 5
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat 5 mg orally once weekly for 14-day lead-in, followed by entinostat and nivolumab (PD1 inhibitor)
Study: 39532861
Drug: Neutralizing antibody
Normalized name: Neutralizing antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibody titer
Study: 39532861
Drug: Anti-Spike binding
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Spike binding antibody concentration
Study: 39533115
Drug: Vicadrostat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicadrostat (10 mg)
Study: 39533204
Drug: PEG-rhG-CSF on
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF on day 7 after chemotherapy
Study: 39533204
Drug: PEG-rhG-CSF on
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF on day 3 after chemotherapy
Study: 39533437
Drug: Adaptive strategies
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive strategies for timely treatment adoption
Study: 39534099
Drug: Livmoniplimab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livmoniplimab monotherapy (3mg to 1500mg Q2W)
Study: 39534099
Drug: Livmoniplimab in
Normalized name: Livmoniplimab
DrugBank: Livmoniplimab (DB18939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livmoniplimab in combination with budigalimab (500mg Q4W)
Study: 39534390
Drug: PEMF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEMF therapy plus eccentric exercise
Study: 39534593
Drug: Carrageenan- and
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrageenan- and sorbitol-containing nasal spray (CS)
Study: 39534972
Drug: Brexpiprazole 2
Normalized name: brexpiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 2 or 3 mg/day
Study: 39535462
Drug: Tozorakimab 60
Normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tozorakimab 60 mg
Study: 39535462
Drug: Tozorakimab 300
Normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tozorakimab 300 mg
Study: 39535462
Drug: Tozorakimab 600
Normalized name: TOZORAKIMAB
DrugBank: MEDI3506 (DB16473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tozorakimab 600 mg
Study: 39535685
Drug: IXE/IXE (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXE/IXE (continuous treatment)
Study: 39535685
Drug: IXE/PBO (interrupted
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXE/PBO (interrupted treatment)
Study: 39535685
Drug: IXE (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXE (continuous treatment)
Study: 39535812
Drug: Symptom screening
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom screening with SSPedi (daily for 5 days)
Study: 39536019
Drug: Home-based active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based active tDCS (HB-a-tDCS) on the left dorsolateral prefrontal cortex (l-DLPFC)
Study: 39536238
Drug: Tirzepatide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (all doses combined)
Study: 39536246
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antioxidant supplements)
Study: 39536433
Drug: CDK 4/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK 4/6 inhibitors (CDK 4-6i)
Study: 39536433
Drug: Capecitabine (second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (second-line treatment)
Study: 39536433
Drug: Taxane-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane-based chemotherapy (second-line treatment)
Study: 39536433
Drug: Everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus plus exemestane (second-line treatment)
Study: 39536433
Drug: Fulvestrant (second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (second-line treatment)
Study: 39536433
Drug: Second-line treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatments (overall)
Study: 39536455
Drug: Ad26/protein preF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26/protein preF RSV vaccine
Study: 39536477
Drug: 3-antigen HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-antigen HBV vaccine (3-A-HBV)
Study: 39536477
Drug: 1-antigen HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-antigen HBV vaccine (1-A-HBV)
Study: 39536780
Drug: HIFES and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIFES and Sync RF+ treatment (single 20-min treatment on the submental area)
Study: 39536847
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy in patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA
Study: 39536847
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone in patients with nonelevated hsCRP and noncarrier of CYP2C19 LoFA
Study: 39536847
Drug: Dual/single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual/single antiplatelet therapy in patients with elevated hsCRP
Study: 39537191
Drug: Standard dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel)
Study: 39537385
Drug: Drug-free group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free group (both GC and HCQ withdrawal)
Study: 39538001
Drug: Avacincaptad pegol
Normalized name: Avacincaptad pegol
DrugBank: Avacincaptad pegol (DB15165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avacincaptad pegol (ACP) 2 mg
Study: 39538139
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication (various classes including thiazide diuretics, ACE inhibitors, ARBs, calcium channel blockers)
Study: 39538139
Drug: Guideline-based antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based antihypertensive therapy